2-(2,4,5-substituted-anilino)pyrimidine compounds
The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising such compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of such compounds and to methods of treatment of diseases mediated by various different forms of EGFR using such compounds and salts thereof.
1. A compound of Formula (I)
or a pharmaceutically acceptable salt thereof, wherein:
G is 1H-indol-3-yl or 1-methyl-1H-indol-3-yl;
R 1 is hydrogen;
R 2 is methoxy; and
R 3 is [2-(dimethylamino)ethyl](methyl)amino or [2-(methylamino)ethyl](methyl)amino.
2. The compound of Formula (I) as claimed in claim 1 which is: N-(2-[2-dimethylaminoethyl-methylamino]-5-{[4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-4-methoxyphenyl)-prop-2-enamide or a pharmaceutically acceptable salt thereof.
3. The compound of Formula (I) as claimed in claim 1 which is: N-(4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}-2-[methyl-(2-methylaminoethyl)amino]-phenyl)prop-2-enamide or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising a compound of Formula (I) as claimed in any one of claims 1 to 3 , or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically-acceptable diluent or carrier.
5. A method for treating lung cancer in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of the compound of Formula (I) as claimed in any one of claims 1 to 3 , or a pharmaceutically acceptable salt thereof.
6. The method of claim 5 , wherein the lung cancer is non-small cell lung cancer.